• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Patent Foramen Ovale Closure —Harnessing Clinical Trial Evidence to Inform Individualized Treatment Decisions
According to some estimates, approximately one-quarter of the general US population has a patent foramen ovale (PFO). With such a high prevalence, clinicians frequently attempt to determine whether a PFO has had a causal role among patients who experience an unexplained stroke, and whether closing the PFO might reduce the risk of recurrent stroke. Several randomized clinical trials have compared the outcomes of PFO closure vs treatment with antiplatelet or anticoagulation agents. In 2016, the American Academy of Neurology conducted a systematic review of 3 trials and concluded that clinicians “should not routinely offer ...
Source: JAMA - December 14, 2021 Category: General Medicine Source Type: research

Management of Patients With a Patent Foramen Ovale With History of Stroke or TIA
This Clinical Guidelines Synopsis summarizes the American Academy of Neurology ’s practice advisory update on management of patients with a patent foramen ovale who have a history of stroke or transient ischemic attack.
Source: JAMA - January 5, 2021 Category: General Medicine Source Type: research

Spider Venom Peptide May Protect Neurons After Stroke
A disulfide-rich spider venom peptide reduced brain damage in rats when given up to 8 hours after a stroke, according to a recentstudy published in theProceedings of the National Academy of Sciences.
Source: JAMA - May 2, 2017 Category: Journals (General) Source Type: research